COGT
Cogent Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$31.50
−5.09%Next report
Analyst consensus
- Next report date
- Nov 6, 2026
- EPS estimate
- -$0.57
- Revenue estimate
- $750.0K
Latest reported
- Last report date
- Aug 10, 2026
- EPS actual
- -$0.52
- EPS estimate
- -$0.55
- Revenue actual
- —
- Revenue estimate
- $1.0K
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 3
- EPS misses (12Q)
- 8
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- +1.5%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $54
- PT range
- $52 – $55
- Analysts
- 4
4 Buy0 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 10, 2026 | -$0.55 | -$0.52 | Beat 6.30% | — |
| Jun 3, 2026 | -$0.53 | -$0.53 | In line | — |
| Mar 11, 2026 | -$0.51 | -$0.55 | Miss -7.84% | — |
| Nov 7, 2025 | -$0.54 | -$0.50 | Beat 7.41% | — |
| Feb 26, 2024 | -$0.54 | -$0.63 | Miss -16.67% | $5.6M |
| Nov 2, 2023 | -$0.50 | -$0.64 | Miss -28.00% | — |
| Mar 14, 2023 | -$0.50 | -$0.56 | Miss -12.00% | — |
| Nov 14, 2022 | -$0.51 | -$0.50 | Beat 1.96% | — |
| Mar 15, 2022 | -$0.55 | -$0.61 | Miss -10.91% | — |
| Nov 10, 2021 | -$0.43 | -$0.48 | Miss -11.63% | — |
| Aug 16, 2021 | -$0.39 | -$0.43 | Miss -10.26% | — |
| Mar 16, 2021 | -$0.30 | -$6.03 | Miss -1910.00% | $0.00 |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 6, 2026